Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Pulmonary/Respiratory Diseases | Family Medicine | Immunology | Infections and Infectious Diseases
 Disease Category: Bronchitis
Location: United States, NC

Trial Information

Chronic Bronchitis Trial for Patients with at least 2 Breathing Exacerbations in the Past Year

The purpose of this study to evaluate the effect of Roflumilast 500 mg on exacerbation rate in patients with COPD treated with a Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS).

Patient Inclusion Criteria:

  • Age 40+
  • Diagnosis of COPD for at least 12 months
  • Currently taking Advair 250/50 or Symbicort 160/4.5 for at least 3 months
  • 2 documented breathing exacerbations within the past 12 months

Patient Exclusion Criteria:

  • Daily oxygen use of over 15 hours
  • Breathing exacerbation in the past 4 weeks
  • Heart attack in the past 6 months
  • Any other major cardiac problems

Mary Preisel, Marketing/Clinical Research Coordinator
American Health Research
1918 Randolph Rd, Suite 440
Charlotte, NC 28207
Phone: 704-325-6700
Email: Mpreisel@ahres.com

View Map

Research Center Information: American Health Research

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.